Welcome to our dedicated page for Pyxis Oncology SEC filings (Ticker: PYXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Every quarter, biotech investors hunt for clues about trial progress, financing needs, and dilution risk hidden deep inside regulatory documents. If you’ve ever typed “Pyxis Oncology SEC filings explained simply” into a search bar, you know how hard it is to extract meaningful insights from dense 10-Ks and 8-Ks. Stock Titan’s AI turns those pages into plain-language highlights so you can focus on decision making, not document wrangling.
Here’s where you’ll find answers faster:
- Real-time alerts: Pyxis Oncology Form 4 insider transactions real-time, including every Pyxis Oncology executive stock transactions Form 4.
- Earnings clarity: Access the Pyxis Oncology quarterly earnings report 10-Q filing and get instant AI commentary.
- Annual deep dive: Pyxis Oncology annual report 10-K simplified with side-by-side ratios, cash runway metrics, and risk factor tagging.
- Event tracking: Pyxis Oncology 8-K material events explained within minutes of posting.
- Governance focus: Read the Pyxis Oncology proxy statement executive compensation with contextual benchmarks.
Whether you’re modeling future dilution or comparing R&D burn across oncology peers, our platform connects each data point back to the source. Drill into Pyxis Oncology insider trading Form 4 transactions, splice them with clinical milestone dates, and see if buying aligns with positive data hints. The integrated dashboard pairs Pyxis Oncology earnings report filing analysis with sector benchmarks, giving context to items such as trial accrual costs and licensing revenue. It’s all part of understanding Pyxis Oncology SEC documents with AI—so you spend more time valuing the science and less time scrolling.
Pyxis Oncology (PYXS) reported Q3 2025 results, highlighting ongoing R&D investment and a going concern warning. The company posted a net loss of $22.0 million for the quarter on zero revenue. Operating expenses were $23.5 million, including $17.8 million in research and development and $5.7 million in general and administrative costs.
As of September 30, 2025, Pyxis held $76.3 million in cash, cash equivalents, and short‑term investments, with total assets of $105.6 million and stockholders’ equity of $68.8 million. Net cash used in operating activities was $53.1 million for the nine months ended September 30, 2025. The company disclosed that current liquidity will not be sufficient to fund operations over the next 12 months, which raises substantial doubt about its ability to continue as a going concern.
Pipeline updates center on micvotabart pelidotin (MICVO). The FDA granted Fast Track Designation in February 2025 for recurrent/metastatic HNSCC monotherapy after platinum and anti‑PD-(L)1 therapy. Pyxis recognized $2.8 million in milestone revenue in the nine‑month period tied to Suvemcitug approval in China. Common shares outstanding were 62,264,215 as of October 31, 2025.
Pyxis Oncology (PYXS) furnished a Form 8-K stating it issued a press release with financial results for the quarter ended September 30, 2025 and a corporate update. The press release is provided as Exhibit 99.1.
The company indicated the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.
GordonMD entities and Craig D. Gordon report a passive 13G stake in Pyxis Oncology (PYXS). The filing shows that GordonMD Global Investments LP, GordonMD Long Biased Master Fund LP, GordonMD Long Biased GP LLC and Craig D. Gordon each report shared voting and dispositive power over 3,834,740 shares of Pyxis common stock, representing 6.2% of the class. All reported securities are owned by advisory clients of GordonMD Global Investments LP, with GordonMD Long Biased Master Fund LP identified as one advisory client that may hold more than 5%. The filing certifies the position is not intended to change or influence control of the issuer and includes a joint filing agreement and a control-person identification exhibit.
Pyxis Oncology (PYXS) is a clinical-stage oncology company focused on micvotabart pelidotin and reports significant historical losses with the expectation of continued losses while it advances development. The company has 62,018,135 shares outstanding as of June 30, 2025 and 190,000,000 shares authorized. It states a need for substantial additional capital and that failure to raise funds could delay or cut research, development or commercialization efforts. Preclinical and early clinical signals for micvotabart pelidotin are highlighted: robust tumor growth inhibition across patient-derived xenograft models, complete responses in multiple indications, tolerability in animal studies, and enhanced efficacy in combination with anti-PD-1. The company plans two ~20-patient expansion cohorts at 5.4 mg/kg IV Q3W with preliminary data expected in the second half of 2025 and the first half of 2026. Material business risks include regulatory, manufacturing, intellectual property and third-party reliance, and the company recorded no federal income tax provision for recent periods.
Pyxis Oncology (PYXS) Form 8-K – Item 8.01
On 31 Jul 2025 the company amended the ClinicalTrials.gov record for its first-in-human, open-label Phase 1 monotherapy trial of micvotabart pelidotin (MICVO, formerly PYX-201; NCT05720117). The revision increases the maximum number of participants that may be enrolled in both dose-escalation (Part 1) and dose-expansion (Part 2) cohorts. Management states the change is procedural and does not alter prior guidance on the expected head-and-neck squamous cell carcinoma (HNSCC) enrollment disclosed in the 15 May 2025 10-Q.
No safety, efficacy, or financial data were released, and all other disclosure items remain unchanged.
Pyxis Oncology, Inc. (Nasdaq: PYXS) filed an 8-K reporting the voting results of its June 18, 2025 virtual Annual Meeting of Stockholders.
Quorum: 43,996,450 shares (≈71% of the 61,947,665 shares outstanding as of the April 21, 2025 record date) were represented.
Proposal 1 – Election of Class I Directors (term through 2028):
- Dr. Santhosh Palani, Ph.D., CFA: 22,056,449 FOR / 7,314,363 WITHHELD / 14,625,638 broker non-votes
- Mr. Darren Cline: 22,028,914 FOR / 7,341,898 WITHHELD / 14,625,638 broker non-votes
- Dr. Rachel Humphrey, M.D.: 21,357,102 FOR / 8,013,710 WITHHELD / 14,625,638 broker non-votes
All nominees obtained simple-majority support and were elected.
Proposal 2 – Ratification of Independent Auditor: Ernst & Young LLP was re-appointed for fiscal 2025 with 43,733,259 FOR, 233,563 AGAINST and 29,628 ABSTAIN; no broker non-votes.
The filing contains no financial performance data, strategic updates or other material transactions. The matters voted on are routine governance items; both proposals passed comfortably, indicating continued shareholder support for the board slate and the external auditor.
FAQ
What is the current stock price of Pyxis Oncology (PYXS)?
What is the market cap of Pyxis Oncology (PYXS)?
